Device Trial Radar · NCT04632784
Clinical Trial With Artiflex Presbyopic (Artiplus)
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
Nov 12, 2021
Primary completion
Nov 26, 2023
Study completion Nov 26, 2026
Sponsor
- Lead sponsor
- Ophtec BVNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 17, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the effectiveness and safety of the multifocal Artiflex Presbyopic (Artiplus) intraocular lens.
Conditions
- Presbyopia
- Ametropia
- Refractive Errors
- Myopia
- Hyperopia
Interventions
Artiflex Presbyopic (Artiplus) implantationDevice
Implantation of iris-fixated multifocal Artiflex Presbyopic IOL (Artiplus)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in monocular and binocular uncorrected near visual acuity (UNVA)Time frame: 3 years
- Improvement in monocular and binocular corrected near visual acuity (CNVA)Time frame: 3 years
- Improvement in monocular and binocular distance corrected near visual acuity (DCNVA)Time frame: 3 years
21 more outcomes with a free account
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
GM st. Mary's Eye clinic
Busan, Busan, South Korea
Nune Eye Hospital Daegu
Seoul, Seoul, South Korea
SU Yonsei Eye Clinic
Seoul, Seoul, South Korea
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.